How to Manage Import and Export of Investigational Products in ASEAN Clinical Trials

The import and export of Investigational Products (IP) is a critical operational step in conducting clinical trials across the ASEAN region. Each member state has its own set of regulatory, customs, and documentation requirements that sponsors and clinical research organizations (CROs) must comply with. Navigating these differing standards is essential to avoid delays, ensure GMP compliance, and maintain the integrity of the product.

This article serves as a tutorial for regulatory affairs professionals, logistics coordinators, and sponsors looking to conduct clinical trials in Southeast Asia. We explore ASEAN-specific requirements for importing and exporting IPs, the necessary licenses and documents, and how to establish a harmonized logistics strategy across the region.

What Are Investigational Products?

Investigational Products are pharmaceutical forms of active ingredients or placebo being tested or used as a reference in a clinical trial. These include tablets, capsules, injectables, biologics, and vaccines. IPs must be handled with care, especially during cross-border transport, to ensure their identity, strength, quality, and purity remain intact.

Key Regulatory Stakeholders in ASEAN:

• Health Science Authority (HSA) – Singapore
• Drug Control Authority (DCA) – Malaysia
• Food and Drug Administration (FDA) – Philippines and Thailand
• Ministry of Health (MOH) – Vietnam, Indonesia, Cambodia, Laos
• National Ethics Committees and Customs Agencies

These authorities work in coordination with customs departments and ethics committees to regulate the entry and exit of clinical trial materials. Depending on the country, either the sponsor, CRO, or a local legal representative must initiate the import/export process.

Import License Requirements Across ASEAN:

1. Singapore:

The import of IPs requires a Clinical Trial Certificate (CTC) issued by HSA. Upon CTC approval, an import license is granted through the Pharmaceutical Regulatory Framework (PRISM) online portal. Cold chain products must meet GDP and temperature monitoring requirements.

2. Malaysia:

The DCA requires sponsors to apply for a Clinical Trial Import License (CTIL). A local licensed importer must handle customs clearance. For multi-site trials, each site must be listed in the CTIL application. Separate CTILs are needed for comparators or ancillary products.

3. Thailand:

Import permits are granted by the Thai FDA under the Ministry of Public Health. Sponsors must engage local importers registered with the FDA. Specific labeling, storage, and retention criteria apply, and the documentation must be in Thai.

4. Indonesia:

Importation of IPs must go through Badan POM (Indonesia’s National Agency of Drug and Food Control). The sponsor must partner with a locally registered entity and secure a Clinical Trial Notification (CTN) before initiating customs procedures.

5. Philippines:

Import licenses are granted by the Philippine FDA after ethics approval is secured from a PHREB-accredited committee. Importers must have a License to Operate (LTO). Customs clearance can be delayed if documents are incomplete or not in sync with the approved protocol.

6. Vietnam:

The Ministry of Health oversees IP importation through the Department of Science, Technology and Training (DSTT). A clinical trial approval letter must accompany the import license request. Temperature data loggers are often required for biologics or vaccines.

Other ASEAN countries follow similar procedures, although they may rely more heavily on manual submissions and paper-based documentation.

Essential Documents for IP Import/Export:

1. Clinical Trial Protocol and Investigator Brochure
2. Informed Consent Forms
3. Ethics Committee Approval Letter
4. Import License or CTIL/CTN Approval
5. Product Labeling Information and GMP Certificate
6. Customs Invoice and Packing List
7. Temperature Monitoring Plans and Storage Conditions
8. SOPs for IP Handling and Accountability

Using standardized Pharma SOP templates can streamline the preparation and review of these documents, reducing processing time.

Best Practices for ASEAN Import/Export Compliance:

• Engage with local regulatory consultants familiar with national nuances
• Ensure your logistics partner understands cold chain requirements
• Cross-check customs HS codes and labeling with local regulations
• Maintain an audit trail for each shipment, including deviations or delays
• Pre-clear shipments by sharing documentation in advance with customs brokers

For IPs with short shelf lives, real-time tracking and predictive logistics planning can mitigate risks associated with customs delays or port congestion.

ASEAN GCP and Import Oversight:

As part of the ASEAN GCP Guidelines, sponsors must ensure that the IP is manufactured and handled in accordance with Good Manufacturing Practices (GMP). Customs clearance is often contingent on the inclusion of a GMP certificate and cold chain SOPs.

According to CDSCO and USFDA expectations, compliance lapses in import/export documentation can lead to warning letters, delays, or trial termination. ASEAN countries are aligning increasingly with these expectations to maintain global credibility.

Common Challenges and Mitigation Strategies:

• Language Barriers: Translate critical documents into local languages as required
• Customs Delays: Pre-engage with national customs to understand evolving expectations
• Temperature Excursions: Use validated temperature monitoring devices with real-time alerts
• Labeling Non-compliance: Follow country-specific rules regarding expiry dates, language, and warnings

IP Export Considerations Post-Trial:

Once a trial concludes, IP destruction or re-export is governed by local rules. Sponsors must:

• Submit a close-out report to national regulatory authorities
• Request permission for destruction or re-export
• Provide reconciliation reports showing usage and inventory
• Maintain accountability logs for audit readiness

In some cases, ethics committees also require evidence that remaining IP was disposed of per protocol and without environmental harm.

Conclusion

The import and export of investigational products in ASEAN clinical trials requires meticulous planning, strong documentation, and clear understanding of country-specific requirements. Sponsors must collaborate with local partners, logistics experts, and customs brokers to streamline operations and avoid trial disruptions. Leveraging platforms like Stability Studies to track shelf life and cold chain integrity further strengthens compliance and quality assurance across multi-country studies.